ClinicalTrials.gg
CompletedNCT01439100Updated Feb 6, 2014

A Randomised Placebo Controlled Study of OXN PR for Severe Parkinson's Disease Associated Pain

A Phase 3 interventional study of Oxycodone/Naloxone Prolonged Release tablets and Placebo in Parkinson's Disease With Severe Pain, sponsored by Mundipharma Research GmbH & Co KG. Completed at 31 sites in 7 countries. Open to participants aged 25 Years and older. Per ClinicalTrials.gov, last updated 2014-02-06.

Sponsored by Mundipharma Research GmbH & Co KG (part of Mundipharma) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
172
Allocation
Randomized
Ages
25 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 263 studies in Parkinson Disease with a site in Germany — 41 open to participants now, 53 under way, 2 of them phase 3. Parkinson Disease · Germany.

Planned enrollment
73rd of 198
172 · median 106
Started
2011
with 11 others
Phase 3
65 of 263
2 open now
Registered
91st of 263
by date

Among the 263 studies in Parkinson Disease with a site in Germany, this one is the 73rd largest by planned enrollment of the 198 interventional ones that give a count, is one of 12 that started in 2011, is one of 65 in phase 3, and was the 91st registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,087 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

41 of the 263 studies in Parkinson Disease with a site in Germany are open now. Recruiting first, the newest first:

36 more — sign in →

All 41 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 750 Parkinson Disease studies recruiting now, 312 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 190 take healthy volunteers.

This study: 25 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 263 studies in Parkinson Disease with a site in Germany, or all of them as a file.
02

Study summary

To demonstrate superiority of OXN PR compared to placebo with respect to analgesic efficacy in subjects with chronic severe pain associated with Parkinson's disease (PD), as assessed by averaged 24 hour pain scores collected for 7 days prior to the clinic visits

Read the detailed description

Pain management in PD is a recognised unmet need. Estimates of incidence vary in the literature from 29% to 83%. The types and sources of pain experienced by PD patients vary and include: musculoskeletal pain, PD related chronic pain, fluctuation-related pain, nocturnal pain, coat-hanger pain, oro-facial pain and peripheral limb or abdominal pain (also including drug-induced pain). Whilst modifications to dosing of dopaminergic therapy represents the most common method of controlling some of these pain symptoms, this must be balanced against the worsening of side effects of increased doses of this treatment type.

Oxycodone hydrochloride and naloxone hydrochloride dihydrate combined oral prolonged release tablets (OXN PR), is the investigational product to be used in this study. OXN PR is a prolonged release tablet consisting of oxycodone and naloxone in a 2:1 ratio. Due to the local competitive antagonism of the opioid receptor-mediated oxycodone effect by naloxone in the gut, naloxone reduces opioid-associated bowel dysfunction.

The purpose of this study is to investigate whether effective pain control for the treatment of PD associated pain may be achieved with OXN PR. The secondary considerations for this study are to examine whether OXN PR may offer any additional benefits to the patients Quality of Life or symptoms of PD. If effective pain relief can be achieved with an analgesic without the side effects described in above, this could reduce the need to increase the dose of dopaminergic medications to manage pain, and therefore reduce the negative side effects of dopaminergic therapy described above. Given the prevalence of constipation in this patient population the bowel sparing effects of the OXN PR combination treatment may provide an ethical rationale for its use over that of other opioids.

03

Conditions studied

  • Parkinson's Disease With Severe Pain

Keywords

  • Parkinson's disease
  • severe pain
  • OXN PR
  • randomised
04

Who can participate

Ages eligible
25 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males and females, age of 25 years or over
  2. Able to provide written
  3. Primary diagnosis of Parkinson's disease Stage II-IV)
  4. Graded as having severe pain
  5. An average pain score of 6 or above on an 11 point NRS, over the previous 7 days
  6. Female subjects willing to use an adequate and highly effective method of throughout the study.
  7. Subjects likely to benefit from WHO step III opioid therapy for the duration of the study
  8. Subjects must not have received opioid containing medication in the last 6 months on a regular basis
  9. Receiving stable treatment for Parkinson's disease for at least 4 weeks prior to randomisation
  10. Subject does not have visual or auditory impairments that would reduce their ability to complete study questionnaires or be unable to receive instructions for these
  11. Concomitant medication (including co-analgesic) use anticipated to remain stable throughout the Double-Blind Phase of the study
  12. Subjects willing and able to participate in all aspects of the study and comply with the use of study medication.

Open-Label Extension Inclusion Criteria

The aim of the Open-Label Phase is to ensure a safe transfer of all subjects to a subsequent pain treatment after the study. Subjects must:

  1. Still meet general inclusion criteria for Double-Blind Phase; subjects do not have to meet inclusion 5, 6, 9 \& 12
  2. Have completed the Double-Blind Phase or discontinued early but have had at least 8 weeks treatment with study medication.

Exclusion criteria

Exclusion Criteria

Subjects who are to be excluded from the study are those who meet any of the following criteria:

Medical Conditions

  1. Cognitive impairment as assessed with the scoring 24 or less
  2. History of psychosis (hallucinations, delusions, etc.)
  3. History of drug or alcohol abuse or current compulsive addictive use of drugs or alcohol
  4. Parkinsonian-like disease secondary to drug therapy side-effects e.g. due to exposure to medications that deplete dopamine (reserpine, tetrabenazine) or block dopamine receptors (neuroleptics, antiemetics)
  5. Parkinson-plus syndromes e.g. progressive supranuclear palsy (PSP) and the multiple system atrophies (MSA)
  6. Females who are pregnant (positive β-hCG test) or lactating
  7. Any other to use of the opioid study medication(s) as per the SmPC/IB:

    • to the active substances or to any of the
    • Any situation where opioids are contraindicated
    • Severe respiratory depression with hypoxia and/or hypercapnia
    • Severe
    • Cor pulmonal
    • Severe bronchial asthma
    • Non-opioid induced paralytic ileus
    • Moderate to severe hepatic impairment (see exclusion criterion 16)
  8. Any other contraindications to use of the study Double-Blind Phase rescue medication as per the SmPC:

    • known hypersensitivity to levodopa or benserazide
    • contra-indicated in narrow-angle glaucoma (it may be used in wide-angle glaucoma provided that the intra-ocular pressure remains under control); severe psychoneuroses or psychoses; severe endocrine, renal, hepatic or cardiac disorders
    • should not be given in conjunction with, or within 2 weeks of withdrawal of, monoamine oxidase (MAO) inhibitors, except selective MAO-B inhibitors (e.g. selegiline) or selective MAO-A inhibitors (e.g. moclobemide) unless selective MAO inhibitors are given in combination in which case it is contraindicated
    • not be used in persons who have a history of, or who may be suffering from, a malignant melanoma
  9. Subjects with any of the following as determined by medical history, clinical laboratory tests, results, and physical examination, that would place the subject at risk upon exposure to the study medication:

    • myxoedema
    • untreated hypothyroidism
    • Addison's disease
    • increase of intracranial pressure
    • uncontrolled seizures or convulsive disorder
    • evidence of cardiovascular, renal, hepatic, gastrointestinal (e.g. paralytic ileus), or psychiatric disease (subjects with controlled co-morbidities may be included following agreement with the Medical Monitor) Contraindicated Treatments
  10. Treatment with Deep Brain Stimulation
  11. Subjects receiving hypnotics or other central nervous system (CNS) depressants that, in the Investigator's opinion, may pose a risk of additional CNS depression with opioids study medication
  12. Subjects presently taking, or who have taken, naloxone or naltrexone less than or equal to 30 days prior to the Screening Visit
  13. Subjects who have received an medicinal product within 30 days of study entry (defined as the start of the Screening Phase)
  14. Any current use of an opioid other than the study medication provided
  15. Subjects with a positive urine drug test at Screening Visit 1, which indicates unreported illicit drug use or unreported use of a concomitant medication not required to treat the Subjects' medical condition(s) Laboratory Exclusions
  16. Abnormal parameters as defined:

    • (AST; SGOT) > 3 times the
    • alanine aminotransferase (ALT; SGPT) > 3 times the upper limit of normal
    • alkaline phosphatase levels > 3 times the upper limit of normal
    • gamma glutamyl transpeptidase (GGT or GGTP) > 3 times the upper limit of normal
    • Abnormal total and/or creatinine level(s) > 1.5 times the upper limit of normal. Subjects whose total bilirubin levels or creatinine levels are below the lower limit of normal can participate in the study if they meet the criteria below:
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
172 participants (estimated)

Study arms

  • Active comparator
    OXN PR

    Oxycodone/Naloxone Prolonged Release tablets

    Drug: Oxycodone/Naloxone Prolonged Release tablets

  • Placebo comparator
    Dummy tablet

    Placebo

    Drug: Placebo

Interventions

  • DrugOxycodone/Naloxone Prolonged Release tablets
  • DrugPlacebo

    Dummy tablet

06

Study locations

31 sites
  • Fakultní nemocnice u sv. Anny v Brně Neurologická klinika
    Brno, Czech Republic
  • Poliklinika Choceň Neuroligická ambulance
    Chocen, Czech Republic
  • Fakultní nemocnice Plzeň Neurologická klinika
    Plzeň-Lochotín, Czech Republic
  • Neurologická ambulance
    Policka, Czech Republic
  • CTC Rychnov nad Kněžnou s.r.o.
    Rychnov nad Kněžnou, Czech Republic
  • Neurologie Berlin
    Berlin-Steglitz, Germany
  • Ruhr Universität Bochum St. Josef-Hospital
    Bochum, Germany
  • Universitätsmedizin Göttingen Georg-August-Universität
    Göttingen, Germany
  • Zentrum für Altersmedizin
    Haag i. OB, Germany
  • Paracelsus-Elena-Klinik
    Kassel, Germany
  • Uniklinik Leipzig
    Leipzig, Germany
  • Philipps-Universität
    Marburg, Germany
  • Asklepios Fachklinikum Abteilung für Neurologie
    Stadtroda, Germany
  • Uniklinik Ulm
    Ulm, Germany
  • Szent János Kórháza és Észak-budai Egyesített Kórházaik
    Budapest, Hungary
  • Kenézy Kórház-Rendelőintézet Egészségügyi Szolgáltató Kft.
    Debrecen, Hungary
  • Szent Pantaleon Kórház-Rendelőintézet Dunaújváros
    Dunaújváros, Hungary
  • Vaszary Kolos Kórház Esztergom
    Esztergom, Hungary
  • Petz Aladár Megyei Oktató Kórház
    Győr, Hungary
  • Bács-Kiskun Megyei Kórháza
    Kecskemét, Hungary
  • NZOZ Synapsa
    Kielce, Poland
  • Krakowska Akademia Neurologii Sp. z o.o.
    Krakow, Poland
  • Spitalul Clinic de Neuropsihiatrie
    Craiova, Jud. Dolj, Romania
  • Hospital Clínic i Provincial de Barcelona
    Barcelona, Spain
  • USP Institut Universitari Dexeus
    Barcelona, Spain
  • Hospital Universtario La Paz
    Madrid, Spain
  • Hospital General de Catalunya
    Sant Cugat, Barcelona, Spain
  • Fairfield General Hospital Pennine Acute NHS Trust
    Bury Great Manchester, United Kingdom
  • King's College Hospital NHS Foundation Trust
    London, United Kingdom
  • Royal Preston Hospital
    Preston, United Kingdom
  • City General Hospital, Pharmacy Dept, Newcastle Road
    Stoke on Trent, United Kingdom
07

References and documents

Publications

  • Trenkwalder C, Chaudhuri KR, Martinez-Martin P, Rascol O, Ehret R, Valis M, Satori M, Krygowska-Wajs A, Marti MJ, Reimer K, Oksche A, Lomax M, DeCesare J, Hopp M; PANDA study group. Prolonged-release oxycodone-naloxone for treatment of severe pain in patients with Parkinson's disease (PANDA): a double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2015 Dec;14(12):1161-70. doi: 10.1016/S1474-4422(15)00243-4. Epub 2015 Oct 19. PubMed 26494524 ↗
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2011, a primary completion of Aug 2013 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2011
First posted
Sep 22, 2011
Start
Oct 2011
Primary completionActual
Aug 2013
CompletionActual
Oct 2013
Last update
Feb 6, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01439100
Responsible party
Sponsor
First posted
Sep 22, 2011
Start date
Oct 2011
Primary completion
Aug 2013
Completion
Oct 2013
Last update
Feb 6, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion